Ludwig Kappos, MSVirtual2020 – OPTIMUM Study (Part 1)
It was an honour to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) around his presentation, a sub analysis of the OPTIMUM study (ClinicalTrials.gov identifier: NCT02425644), entitled: P0071 – Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study.
1. Could you give us a brief overview of the OPTIMUM study and its major findings? (0:06)
2. What were the findings of your analysis of prespecified magnetic resonance imaging-based endpoints and no evidence of disease activity (NEDA) status? (2:58)
See also the 2nd part of this interview here.
Disclosures: Dr Kappos reports receiving grants from Actelion, Allergan, Almirall, Baxalta, Bayer Healthcare, Biogen, CSL Behring, Desitin, Eisai, Excemed, Genzyme, INNO Swiss, Japan Tabacco, Merck, Novartis, Roche, Pfizer, Receptos, Sanofi, Santhera and Teva; other from Neurostatus; and grants from the European Union, Roche Research Foundation, Swiss MS Society and Swiss National Research Foundation.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!